
Mitochondrial fusion promoter M1
CAS No. 219315-22-7
Mitochondrial fusion promoter M1 ( —— )
产品货号. M23990 CAS No. 219315-22-7
线粒体融合启动子 M1 是一种线粒体动态调节剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
10MG | ¥348 | 有现货 |
![]() ![]() |
25MG | ¥640 | 有现货 |
![]() ![]() |
50MG | ¥1077 | 有现货 |
![]() ![]() |
100MG | ¥1831 | 有现货 |
![]() ![]() |
200MG | ¥2722 | 有现货 |
![]() ![]() |
500MG | ¥4560 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Mitochondrial fusion promoter M1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述线粒体融合启动子 M1 是一种线粒体动态调节剂。
-
产品描述Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury.
-
体外实验——
-
体内实验Animal Model:Male Wistar rats (250-300g) receiving cardiac ischemia/reperfusion (I/R)Dosage:2 mg/kg Administration:I.v. 15 minutes before cardiac I/R injury Result:Increased brain mitochondrial fusion.Increased blood-brain barrier (BBB) tight junction protein, and reduced macrophage in?ltration in the brain.Reduced brain mitochondrial dysfunction and apoptosis, but it did not reduce mitochondrial oxidative stress.Reduced the expression of Alzheimer’s disease (AD)-related proteins.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Mitochondria
-
研究领域——
-
适应症——
化学信息
-
CAS Number219315-22-7
-
分子量364.05
-
分子式C14H10Cl4N2O
-
纯度>98% (HPLC)
-
溶解度DMSO:46 mg/mL?(126.35 mM;?Need ultrasonic)
-
SMILESCC(c(cc(cc1)Cl)c1O)=NNc(c(Cl)cc(Cl)c1)c1Cl
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Surinkaew P, et, al. Mitochondrial Fusion Promoter Alleviates Brain Damage in Rats with Cardiac Ischemia/Reperfusion Injury. J Alzheimers Dis. 2020;77(3):993-1003.
产品手册




关联产品
-
Koaburaside monometh...
Koaburaside monomethyl ether is a natural product of Croton, Euphorbiaceae. Koaburaside monomethyl ether can be used as a reference standard.
-
Ethyl oleate
油酸乙酯是纳米结构脂质载体 (NLC) 中的液体脂质成分。 NLC 是一种很有前景的口服反式阿魏酸 (TFA) 给药载体。
-
Hydroxybupropion
Hydroxybupropion 是 Bupropion 的主要活性代谢产物,主要是通过 CYP2B6 代谢的。Bupropion 是一种非典型的抗抑郁剂和戒烟剂。Hydroxybupropion 抑制去甲肾上腺素 (norepinephrine uptake) 的摄取,IC50 值为 1.7 μM。Hydroxybupropion 也是一种 nACh 受体拮抗剂。